The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
Immuno-oncology drugs showing results in hard-to-treat cancers; Express Scripts responds to Anthem lawsuit; BI and Lilly plan outcomes trials for Jardiance
IBM Watson Health's cognitive computing system for oncology tackles one of the leading causes of death worldwide and attempts to eradicate misdiagnoses.
Some 30% of the physicians in the U.S. sold their practices, which in turn commensurately reduced the number of physicians who are willing and able to be called on by sales reps.
The drugmaker instead suggested using an economic model it developed.
The scientific services company expands its portfolio to include expertise in oncology clinical studies.
The regulator's reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today's precision medicine.
Manufacturers team up to study drug combinations, a strategy expected to advance the category.
Bristol-Myers Squibb considered immunotherapy market leader; McKesson buys two cancer-care companies; Bayer names new CEO
Cancer MoonShot 2020 to study childhood cancers; IBM's purchase of Truven provides data about 200 million patients; overdoses tied to benzodiazepines rise
Health economic and outcomes research datasets have rarely been integral to product development and communication plans.
Biden to lead "moonshot" to cure cancer; Pfizer/Allergan merger to create "best pipeline in the industry," CEO says; AMA invests in health tech startup
The drugmaker led a Series C fundraising round totaling $175 million. The funding will be used to accelerate clinical trials.
Twenty percent of publicly funded cancer clinical trials don't enroll enough patients; KaloBios files for bankruptcy; a new MS campaign in Australia uses bicycles
David Meek has been charged with building an oncology arm that matches the company's existing strengths in hematology and immunology.
Britain says Bristol-Myers Squibb's Opdivo is too expensive; Calpers reports 32% boost in specialty drug spending; NIH is funding fewer clinical trials
Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug
Pfizer reveals Ibrance pricing strategy; AMA call for DTC ban may resonate due to pricing debate; Baxalta's Vonvendi receives FDA approval
AstraZeneca plans to incorporate a mobile app that gathers information about side effects in three clinical trials studying an experimental combination therapy for ovarian cancer.
FDA advisers vote against BioMarin's Duchenne drug; the FDA approves Lilly's lung-cancer drug; criticism mounts for Pfizer's proposed deal with Allergan
Opdivo receives another indication; increasing generic prescriptions may boost patient adherence; hep.-C drugs should be prescribed during earlier stages of disease
Addyi off to a slow start; Dr. Robert Califf faces Senate committee on FDA nomination; FDA grants Opdivo Breakthrough Therapy Designation in kidney cancer
Some pharma companies are taking steps to address concerns about the high prices of drugs at a time when Democratic lawmakers are urging price controls.
The campaign marks the drugmaker's foray into oncology DTC advertising as it vies for market share against competing treatment Keytruda.
Company's vaccines chief credits campaigns aimed at grownups with driving US demand for blockbuster vaccine. The remaining cohort will be harder to capture.
Oncologist perception of diagnostics may grow as immuno-oncology treatments move toward first-line use, drugmaker execs say.
Bristol-Myers Squibb's Opdivo expanded indication in lung cancer could push Keytruda to the margins.
Sanofi's Aubagio reduces brain volume loss; cancer specialists avoid pricey cancer meds; analysis says placebo effect is on the rise
Keytruda scored an approval in lung cancer, but its narrow label will likely have it playing second fiddle.
Keytruda approved in non-small cell lung cancer; Enbrel biosimilar inches closer to approval; study finds no link between autism and vaccines
Click here to learn about the Agency Issue.
- When it comes to professional ads, print makes its comeback
- Amgen takes issue with yet-to-be published multiple-myeloma drug report
- How Watson for Oncology is advancing cancer care
- Following positive outcomes data, a new diabetes class is on the rise
- Creative partners should push pharma clients to tell better stories